伊马替尼减少血管渗漏与体外循环大鼠微循环灌注保留及肾损伤标志物降低相关
该研究在体外循环大鼠模型中探讨伊马替尼预防血管渗漏对微循环灌注和器官损伤标志物的影响。结果显示伊马替尼组微循环灌注和氧饱和度优于对照组,血管渗漏和液体复苏需求减少,血浆NGAL浓度降低。提示保护内皮屏障可减轻体外循环后微循环障碍和器官损伤。
要点
- 伊马替尼预防血管渗漏可保留体外循环期间及之后的微循环灌注。
- 伊马替尼组液体复苏需求低于对照组。
- 伊马替尼降低血浆NGAL浓度并减轻肾和肺损伤标志物。
核心结论
- 使用伊马替尼预防内皮屏障功能障碍可保留体外循环期间及之后的微循环灌注和氧合。
- 伊马替尼诱导的内皮屏障完整性保护减少了液体复苏需求并减轻肾和肺损伤标志物。
研究设计与样本
- 雄性Wistar大鼠接受体外循环,随机给予伊马替尼或溶剂对照,每组n=8。
- 采用活体显微镜和反射光谱测量提睾肌微循环灌注和股四头肌微血管氧饱和度。
- 在单独实验中测定伊文思蓝外渗,并检测血浆、肠、肾和肺的器官损伤标志物。
主要发现
- 对照组体外循环开始后灌注微血管数减少40%[9.4(8.6-10.6)降至5.7(4.8-6.2)/显微镜视野;P<0.001 vs 基线],伊马替尼组未见此减少。
- 对照组灌注毛细血管数在整个实验中保持低水平,而伊马替尼组灌注保持正常。
- 伊马替尼组微血管氧饱和度受损程度轻于对照组。
- 伊马替尼减少血管渗漏并降低液体复苏量[3(3-6)vs 12 ml(7-16);P=0.024]。
- 伊马替尼降低血浆中性粒细胞明胶酶相关脂质运载蛋白浓度。
临床怎么用
- 该大鼠模型结果提示保护内皮屏障可能成为减轻体外循环后微循环障碍和器官损伤的潜在策略。
- 伊马替尼在体外循环中的临床转化价值尚需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiopulmonary bypass during cardiac surgery leads to impaired microcirculatory perfusion. We hypothesized that vascular leakage is an important contributor to microcirculatory dysfunction. Imatinib, a tyrosine kinase inhibitor, has been shown to reduce vascular leakage in septic mice. We investigated whether prevention of vascular leakage using imatinib preserves microcirculatory perfusion and reduces organ injury markers in a rat model of cardiopulmonary bypass. METHODS: Male Wistar rats underwent cardiopulmonary bypass after treatment with imatinib or vehicle (n=8 per group). Cremaster muscle microcirculatory perfusion and quadriceps microvascular oxygen saturation were measured using intravital microscopy and reflectance spectroscopy. Evans Blue extravasation was determined in separate experiments. Organ injury markers were determined in plasma, intestine, kidney, and lungs. RESULTS: The onset of cardiopulmonary bypass decreased the number of perfused microvessels by 40% in the control group [9.4 (8.6-10.6) to 5.7 (4.8-6.2) per microscope field; P<0.001 vs baseline], whereas this reduction was not seen in the imatinib group. In the control group, the number of perfused capillaries remained low throughout the experiment, whilst perfusion remained normal after imatinib administration. Microvascular oxygen saturation was less impaired after imatinib treatment compared with controls. Imatinib reduced vascular leakage and decreased fluid resuscitation compared with control [3 (3-6) vs 12 ml (7-16); P=0.024]. Plasma neutrophil-gelatinase-associated-lipocalin concentrations were reduced by imatinib. CONCLUSIONS: Prevention of endothelial barrier dysfunction using imatinib preserved microcirculatory perfusion and oxygenation during and after cardiopulmonary bypass. Moreover, imatinib-induced protection of endothelial barrier integrity reduced fluid-resuscitation requirements and attenuated renal and pulmonary injury markers.
引用
- Koning NJ, de Lange F, van Meurs M, et al. Reduction of vascular leakage by imatinib is associated with preserved microcirculatory perfusion and reduced renal injury markers in a rat model of cardiopulmonary bypass. Br J Anaesth. 2018. PMID: 29793583. doi:10.1016/j.bja.2017.11.095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。